Humalog 100IU/ml Kwikpen contains insulin lispro, a rapid-acting human insulin analog used for the management of diabetes mellitus. It is indicated to improve glycemic control in adults and children with type 1 and type 2 diabetes. Insulin lispro has a faster onset of action compared to regular human insulin, typically beginning to work within 15 minutes after subcutaneous injection, with a peak effect at approximately 1 hour and a duration of action of 2 to 4 hours. This rapid pharmacokinetic profile allows for administration immediately before or shortly after meals to better control postprandial blood glucose levels. The Kwikpen device is a prefilled, disposable insulin delivery system designed for ease of use, enabling accurate dosing and convenient administration. Dosage and timing should be individualized based on the patient’s metabolic needs, blood glucose monitoring results, and meal patterns. Humalog should be used in conjunction with a proper diet and exercise regimen. Caution is advised to avoid hypoglycemia, which is the most common adverse effect. Patients should be educated on recognizing and managing hypoglycemic episodes. Proper storage and handling instructions must be followed to maintain insulin potency. Humalog 100IU/ml Kwikpen is a critical component in intensive insulin therapy for optimal diabetes management.